US · Healthcare · Biotechnology
EPS came in at -0.82 against a street estimate of -0.80 — a miss of 2.5%.
Analysts rate Arvinas Inc a buy (7 buy, 8 hold, 1 sell out of 16) with an average price target of $14.46.
| Fund | Stake |
|---|---|
| BlackRock Inc | 11.64% |
| Vanguard Portfolio Management, LLC | 6.31% |
| D. E. Shaw & Co LP | 5.35% |
| Pfizer Inc | 5.29% |
| Armistice Capital, LLC | 4.28% |
| Vanguard Capital Management, LLC | 4.15% |
| Two Sigma Investments LLC | 3.94% |
| State Street Corp | 3.36% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Arvinas Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.